Tag Archives: CBM

Analysts’ View: Cambrex (CBM), Woodward (WWD), Karyopharm Therapeutics (KPTI)

Brokerage Firm First Analysis Sec upgraded Cambrex Corporation (NYSE:CBM) shares from Outperform to Strong Buy rating while decreasing their price target from $73 to $63.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide.


Woodward, Inc. (NASDAQ:WWD) shares were upgraded by analysts at Barrington Research from Market Perform to Outperform rating with a price target of $98.

Woodward, Inc. designs, manufactures, and services energy control and optimization solutions for the aerospace and industrial markets worldwide.


Investment Analysts at Wedbush upgraded Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares from Neutral to Outperform rating with a price target of $19.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/